Shire suffers amid the end of Adderall
This article was originally published in Scrip
Executive Summary
Shire's second-quarter product sales were hit as expected by a heavy decline in sales of its lead product Adderall XR, after Teva Pharmaceutical Industries launched a generic version in April.